Hodgkin Lymphoma
Approximately 8,200 individuals are diagnosed with Hodgkin lymphoma each year in the United States. Hodgkin lymphoma is most frequently diagnosed among people aged 20-34 years. [1]
Advances
Significant progress has been made in the treatment of patients with Hodgkin lymphoma, with cure rates of 80% or higher using chemotherapeutic approaches. [2] New active agents (e.g., bendamustine and brentuximab) have been introduced that can help control relapsed or refractory Hodgkin lymphoma in order to allow procession to transplant. [3,4]
An accurate assessment of the stage of disease in patients with Hodgkin lymphoma is critical for the selection of the appropriate therapy. [5] Prognostic models that identify patients at low or high risk for recurrence are used to optimize therapy for patients with limited or advanced stage disease. [6]
Hematopoietic cell transplantation (HCT), often autologous but occasionally allogeneic, can be used for recurrent disease. Allogeneic HCT in patients with relapsed/refractory Hodgkin lymphoma has significantly improved over time. A recent single-center study found that 3-year progression-free survival after allogeneic HCT improved from 23% in 2000-2008 to 49% in 2009-2013. The corresponding 3-year overall survival increased from 50% to 84%. [7]
Outcomes
Review outcomes for allogeneic and autologous HCT in patients with Hodgkin lymphoma below. View additional Hodgkin Lymphoma slides showing demographic data and transplant trends.
Data in this section have been prepared by CIBMTR® (Center for International Blood and Marrow Transplant Research), our research program.
Figure 1: Hodgkin Lymphoma Survival, Unrelated HCT
Download slide "Hodgkin Lymphoma Survival, Unrelated HCT"
Figure 2. Hodgkin Lymphoma Survival, Autologous HCT, by Disease Status
Download slide "Hodgkin Lymphoma Survival, Autologous HCT, by Disease Status"
Figure 3. Hodgkin Lymphoma Survival, Allogeneic HCT, by Donor Type
Download slide "Hodgkin Lymphoma Survival, Allogeneic HCT, by Donor Type"
Referral Timing Guidelines
These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [8]
Transplant Consultation Guidelines: Hodgkin Lymphoma
- Primary induction failure
- At first or subsequent relapse
- CR2 or subsequent remission
References
- SEER Stat Fact Sheets: Hodgkin Lymphoma. Website accessed 2 November, 2017. Access
- National Comprehensive Cancer Network (NCCN) Guidelines: Hodgkin Lymphoma, version 2.2013; page MS-2. Access
- Moscowitz AJ. Novel agents in Hodgkin lymphoma. Curr Oncol Rep. 2012; 14(5): 419-423. Access
- Zinzani PL, Derenzini E, Pellegrini C, et al. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. Br J Haematol. 2013; 163(5): 681-683. Access
- Perales M-A, Ceberio I, Armand P, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21(6): 971-983. Access
- Ansell, SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012; 87(12): 1096-1103. Access
- Hegerova L, Cao Q, Lazaryan A, et al. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant. 2017; 52(5): 697-703. Access
- NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation, 2018. Download (PDF)